Acura Pharmaceuticals, Inc.

Other

Pharmaquest Limited

Pharmalogix, Inc.

Halsey Drug Company, Inc.

Vijai Kumar

David Dixon

Divya Tewari

Dilip B Wadgaonkar

Kazimierz Grzegorz Antczak

Charles Auxilium Francis

Zhaiwei Lin

Christopher Arne Kaldahl

Martin H Teicher

Kamal K Midha

Kevin Scott McGuffy

This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

Abuse deterrent compositions and methods of making same

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.

Compositions for deterring abuse of opioid containing dosage forms

Extended release opioid abuse deterrent compositions and methods of making same

Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof

Methods and compositions for deterring abuse of opioid containing dosage forms

Oxycodone is manufactured in high yields and with a high purity using a composition including a thebaine component into 14-hydroxycodeinone and then reduction of 14-hydroxycodeinone to oxycodone.

Process for manufacturing opioid analgesics

Oxycodone is manufactured in high yields and with a high purity using codeine or a salt of codeine as the starting material. The manufacturing process involves the following steps:

Process for manufacturing oxycodone

Process for manufacturing thebaine

An extended-release matrx formulation capable of being directly compressed into tablets comprising metformin hydrochloride blended with specific excipients. The excipients used in the formulation enhance the flow and compaction properties of the drug and insure that the formulation is directly compressible into a tablet containing about 100 mg to about 800 mg, preferably about 250 mg to about 750 mg, of metformin hydrochloride in unit dosage form. Each tablet produced by direct compression of the formulaton has the desired hardness and dissolution characteristics such that the drug is released in the body of the subject over an extended period of time.

Directly compressible extended-release matrix formulation for metformin hydrochloride

A method of treating dysphoria or depression is disclosed in a patient which comprises the step of administering orally or non-orally to said patient, a therapeutically effective amount of 1-threo-methylphenidate or a pharmaceutically acceptable acid addition salt thereof.

Method of treating depression using 1-threo-methylphenidate

Methods and formulations for making extended release bupropion hydrochloride tablets using direct compression, and tablets formed thereby, are provided which combine bupropion hydrochloride, binders such as polyethylene oxide or hydroxypropyl cellulose, a filler such as lactose, glidants and lubricants under low shear conditions to form hard, chip-resistant tablets which exhibit improved cohesiveness and are easily and reproducibly formed without adhering to the compression punches and dies.

Growing community of inventors

Morris Plains, NJ, United States of America

Vijai Kumar